Evidence map›Paper›PMID 40120030›Full record

ReviewInternational ophthalmology2025

Innovative approaches to treatment of eye diseases: advances in stem cell therapy use in ophthalmology.

Victor Oluwatomiwa Ajekiigbe, Chinonyelum Emmanuel Agbo, Ikponmwosa Jude Ogieuhi, Chidera Stanley Anthony, Olajumoke Adesola Adewole, Bisharat Ahmed, Adewunmi Akingbola, Chinemelum Kingsley Nwankwo, Ayomide Timilehin Kayode, Uzochukwu Emmanuel Chima and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Victor Oluwatomiwa AjekiigbeLadoke Akintola University of Technology, Ogbomoso, Nigeria.
Chinonyelum Emmanuel AgboPharmaceutical Sciences, University of Nigeria, Nsukka, Nigeria.
Ikponmwosa Jude OgieuhiSiberian State Medical University, Tomsk, Russia. Jude.ogieuhi@gmail.com.
Chidera Stanley AnthonyUniversity of Calabar, Calabar, Nigeria.
Olajumoke Adesola AdewoleLagos State University College of Medicine, Lagos, Nigeria.
Bisharat AhmedAllama Iqbal Medical College, University of Health Sciences, Lahore, Pakistan.
Adewunmi AkingbolaDepartment of Public Health, University of Cambridge Cambridgeshire Old Trinity Schools, Cambridge, CB2 1TN, England, UK.
Chinemelum Kingsley NwankwoPharmaceutical Sciences, University of Nigeria, Nsukka, Nigeria.
Ayomide Timilehin KayodeLadoke Akintola University of Technology, Ogbomoso, Nigeria.
Uzochukwu Emmanuel ChimaPharmaceutical Sciences, University of Nigeria, Nsukka, Nigeria.
Obed Mercy AdaobiPharmaceutical Sciences, University of Nigeria, Nsukka, Nigeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe human eye, a photo-sensory organ with an array of neuronal and tissue networks, remains susceptible to damage from various diseases and disorders despite its being a flawless masterpiece. It is estimated that over 2 billion people suffer from vision loss with common causative factors such as; age-related macular degeneration (AMD), glaucoma, cataracts, diabetic retinopathy, and infections amongst others. The use of Orthodox procedures has only helped mitigate the pathology; however, it doesn't serve any substantial curative purpose. More recently, the incorporation of new therapies via ocular delivery of nanomaterials and stem cell intervention has helped to change tides in the treatment of various ophthalmic pathologies. MAIN TEXT: This review provides an overview of the current trends and breakthroughs in ophthalmology via stem cell therapy, with emphasis on its types, mechanisms, applications, and benefits. Mesenchymal stem cells which can arise from embryonic or adult origin possess some immunomodulatory effects that contribute to the therapeutic relevance of the MSCs and the ability to evade rejection from the host. However, the major drawback has been uncontrolled growth which can result in unintended side effects. Moreso, religious and ethical issues concerning the employment of MSCs from embryonic origin have also hindered clinical progression with its use. The use of stem cell therapy in the treatment of eye pathologies which is still undergoing clinical trials has shown to be a more viable treatment approach in ophthalmology as it targets retinal degenerative diseases thereby offering novel pathways for vision restoration. And also serves as a revolutionary alternative for treating severe ocular diseases. Stem cell delivery techniques might be quite cumbersome as the eye is a very delicate organ. The therapeutic interventional technique employed is aimed to ensure the reduction or absence of undesired effects in the deposition of the active pharmaceutical ingredient (API) being the stem cells. Techniques such as hydrogel-based injectables, which offer delivery of the APIs to the desired site of action without change in the physicochemical properties of the drug molecule, the scaffold delivery techniques, and the use of 3D bio-printing which can be used to develop scaffolds for retinal degeneration. The employment of artificial intelligence and machine learning in stem cell therapy has shown to be very fast and efficient in stem cell delivery and preventing likely human errors.

conclusionsUnlike conventional treatments that often focus on managing symptoms, stem cells have the unique ability to repair and regenerate damaged tissues, addressing the root causes of the diseases. However, limitations due to economic, regulatory, and ethical challenges have posed barriers to advancing stem cell therapies.

Indexed as

Eye DiseasesOphthalmologyStem Cell TransplantationHumansAge-related macular degenerationHuman embryonic stem cells (hESCs)Human-induced pluripotent stem cells (iPSCs)Mesenchymal stem cells (MSCs)Retinal progenitor cells (RPCs)Stem cell therapy (SCT)

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.